XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

XYRA-FDA-Label

More Like This

PR Newswire associated0

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

PR Newswire associated0

CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies

iRhythm Technologies Receives European Union’s CE Marking Under Medical Device Regulation (EU MDR) for its Zio® monitor and ZEUS System

PR Newswire associated0

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with First-in-Human Success

PR Newswire associated0

Former Lions and Wales Rugby Captain Alun Wyn Jones partners with AliveCor to launch 'Let's Talk Rhythm' campaign to raise awareness of atrial fibrillation

PR Newswire associated0

Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance

Business Wire logo

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation